Research programme: antiviral therapeutics - G.ST Antivirals
Latest Information Update: 23 May 2024
At a glance
- Originator G.ST Antivirals
- Class Antivirals
- Mechanism of Action Undecaprenyl pyrophosphate synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Viral infections
Most Recent Events
- 30 Apr 2024 Preclinical trials in Viral infections (Prevention) in Austria (unspecified route) prior to April 2024 (G.ST Antivirals pipeline, April 2024)
- 30 Apr 2024 Preclinical trials in Viral infections in Austria (unspecified route) prior to April 2024 (G.ST Antivirals pipeline, April 2024)